SEC Form DEF 14A filed by ACADIA Pharmaceuticals Inc.
$ACAD
Biotechnology: Pharmaceutical Preparations
Health Care
Unavailable
Unavailable
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 3/25/2026 | $29.00 | Neutral → Buy | BofA Securities |
| 2/24/2026 | $33.00 | Outperform | Wolfe Research |
| 2/23/2026 | $35.00 | Neutral → Outperform | Mizuho |
| 10/21/2025 | $33.00 | Buy | Citigroup |
| 5/21/2025 | $35.00 | Hold → Buy | Deutsche Bank |
| 2/11/2025 | $22.00 | Hold | Deutsche Bank |
| 1/3/2025 | $23.00 → $20.00 | Buy → Neutral | Guggenheim |
| 10/10/2024 | Mkt Perform | Raymond James |
BofA Securities upgraded ACADIA Pharmaceuticals from Neutral to Buy and set a new price target of $29.00
Wolfe Research initiated coverage of ACADIA Pharmaceuticals with a rating of Outperform and set a new price target of $33.00
Mizuho upgraded ACADIA Pharmaceuticals from Neutral to Outperform and set a new price target of $35.00
4 - ACADIA PHARMACEUTICALS INC (0001070494) (Issuer)
4 - ACADIA PHARMACEUTICALS INC (0001070494) (Issuer)
4 - ACADIA PHARMACEUTICALS INC (0001070494) (Issuer)
S-8 - ACADIA PHARMACEUTICALS INC (0001070494) (Filer)
8-K - ACADIA PHARMACEUTICALS INC (0001070494) (Filer)
10-Q - ACADIA PHARMACEUTICALS INC (0001070494) (Filer)
Submission status for ACADIA PHARMS INC's drug NUPLAZID (SUPPL-16) with active ingredient PIMAVANSERIN TARTRATE has changed to 'Approval' on 05/04/2026. Application Category: NDA, Application Number: 210793, Application Classification: Labeling
Submission status for ACADIA PHARMS INC's drug NUPLAZID (SUPPL-16) with active ingredient PIMAVANSERIN TARTRATE has changed to 'Approval' on 04/27/2026. Application Category: NDA, Application Number: 207318, Application Classification: Efficacy
Submission status for ACADIA PHARMS INC's drug NUPLAZID (SUPPL-14) with active ingredient PIMAVANSERIN TARTRATE has changed to 'Approval' on 04/27/2026. Application Category: NDA, Application Number: 210793, Application Classification: Efficacy
-- Designation underscores the significant unmet need for new treatment options for Alzheimer’s disease psychosis, a serious condition with no FDA-approved therapies -- RADIANT Phase 2 enrollment completed, with topline results now expected September to October 2026 and Phase 3 screening and enrollment underway Acadia Pharmaceuticals Inc. (NASDAQ:ACAD) today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to remlifanserin, an investigational, highly selective, 5-HT2A receptor inverse agonist, for the treatment of hallucinations and delusions associated with Alzheimer’s disease psychosis (ADP). Fast Track designation is designed to facilita
Company to host conference call and webcast on Tuesday, August 4, 2026, at 4:30 p.m. Eastern Time Acadia Pharmaceuticals Inc. (NASDAQ:ACAD) today announced that it will report second quarter 2026 financial results on Tuesday, August 4, 2026, after the close of the U.S. financial markets. Acadia’s management team will also host a conference call and webcast on August 4, 2026, at 4:30 p.m. Eastern Time. The conference call will be available on Acadia’s website, acadia.com under the investors section and will be archived for approximately 90 days. The conference call may also be accessed by registering for the call here. Once registered, participants will receive an email with the dial-in
-- Experienced global HR leader joins Acadia to advance people strategy and support the next phase of growth Acadia Pharmaceuticals Inc. (NASDAQ:ACAD) today announced the appointment of Carl Segerstrom as Chief People Officer, effective July 6. Carl will lead the company’s global people and culture strategy, supporting its next phase of growth as a leading neurological and rare disease company focused on advancing therapies for patients with significant unmet needs. He will serve as a member of Acadia’s executive leadership team. "Carl is a proven global leader with a strong track record of building high-performing organizations and shaping culture to enable business performance," said
-- Experienced global HR leader joins Acadia to advance people strategy and support the next phase of growth Acadia Pharmaceuticals Inc. (NASDAQ:ACAD) today announced the appointment of Carl Segerstrom as Chief People Officer, effective July 6. Carl will lead the company’s global people and culture strategy, supporting its next phase of growth as a leading neurological and rare disease company focused on advancing therapies for patients with significant unmet needs. He will serve as a member of Acadia’s executive leadership team. "Carl is a proven global leader with a strong track record of building high-performing organizations and shaping culture to enable business performance," said
Acadia Pharmaceuticals Inc. (NASDAQ:ACAD) today announced the planned retirement of Elizabeth H.Z. Thompson, Ph.D., Head of Research and Development. Dr. Thompson has decided to retire for personal reasons and informed Acadia of her plans. She will continue in her role as Head of Research and Development until a successor is appointed. After her retirement, Acadia plans to retain Dr. Thompson as a consultant through at least the end of 2026 to ensure scientific and leadership continuity through the planned readout of the Phase 2 clinical study of remlifanserin in Alzheimer's disease psychosis (ADP) and into early Phase 3 clinical study execution. Acadia has initiated a search for a new He
Acadia Pharmaceuticals Inc. (NASDAQ:ACAD) today announced the appointment of Jonathan M. Poole to its Board of Directors, effective March 3, 2026. Mr. Poole will serve on the Company's Audit Committee and brings deep biopharmaceutical finance leadership experience in supporting global growth and innovation across multiple therapeutic areas and modalities. "Jonathan brings extensive biotechnology corporate leadership experience and a proven track record of supporting significant business growth across complex, global organizations," said Stephen R. Biggar, M.D., Ph.D., Chairman of Acadia's Board of Directors. "His appointment further strengthens the Board's financial and operational expert
Company to host conference call and webcast on Tuesday, August 4, 2026, at 4:30 p.m. Eastern Time Acadia Pharmaceuticals Inc. (NASDAQ:ACAD) today announced that it will report second quarter 2026 financial results on Tuesday, August 4, 2026, after the close of the U.S. financial markets. Acadia’s management team will also host a conference call and webcast on August 4, 2026, at 4:30 p.m. Eastern Time. The conference call will be available on Acadia’s website, acadia.com under the investors section and will be archived for approximately 90 days. The conference call may also be accessed by registering for the call here. Once registered, participants will receive an email with the dial-in
- First quarter DAYBUE® GAAP net sales of $101 million, up 20% year-over-year; successful launch of DAYBUE STIX underway - First quarter NUPLAZID® GAAP net sales of $167 million, up 6% year-over-year on a non-GAAP adjusted basis - Reaffirms expectation for topline results from the Phase 2 remlifanserin study in Alzheimer's disease psychosis between August and October 2026 Acadia Pharmaceuticals Inc. (NASDAQ:ACAD), today announced its financial results for the first quarter ended March 31, 2026. "Acadia delivered a solid first quarter of 2026 with total revenues of $268 million, driven by a strong start from DAYBUE, which generated sales of $101 million," said Catherine Owen Adams, C
Company to host conference call and webcast on Wednesday, May 6, 2026, at 4:30 p.m. Eastern Time Acadia Pharmaceuticals Inc. (NASDAQ:ACAD) today announced that it will report first quarter 2026 financial results on Wednesday, May 6, 2026, after the close of the U.S. financial markets. Acadia's management team will also host a conference call and webcast on May 6, 2026, at 4:30 p.m. Eastern Time. The conference call will be available on Acadia's website, acadia.com under the investors section and will be archived there until August 15, 2026. The conference call may also be accessed by registering for the call here. Once registered, participants will receive an email with the dial-in numb
SC 13G/A - ACADIA PHARMACEUTICALS INC (0001070494) (Subject)
SC 13G - ACADIA PHARMACEUTICALS INC (0001070494) (Subject)
SC 13G/A - ACADIA PHARMACEUTICALS INC (0001070494) (Subject)